Effect of Ommaya Capsule on Cerebral Hemorrhage Complicated with Acute Hydrocephalus and its Effect on Blood-brain Barrier Function
-
摘要:
目的 探讨Ommaya囊在脑出血并发急性期脑积水治疗中的应用及对血脑屏障功能和预后的影响。 方法 选取2021年1月至2023年1月安庆一一六医院脑出血并发急性期脑积水患者80例,按照随机数字表法分组,各40例。对照组给予腰大池介入治疗,观察组给予Ommaya囊介入治疗。比较2组治疗效果、治疗前后血脑屏障(BBB)指数、血清S100β蛋白(S100β)、脑脊液细胞数、葡萄糖、髓鞘碱性蛋白(MBP)、美国国立卫生研究院卒中量表(NIHSS)、特异性烯醇化酶(NSE)、氯化物、中国脑卒中临床神经功能缺损量表(CSS)评分及并发症发生情况,并随访6个月,对比2组预后情况。 结果 观察组总有效率90.00%(36/40)高于对照组72.50%(29/40),P < 0.05;治疗后1周、2周观察组血清S100β、MBP、BBB指数、NSE、脑脊液细胞数水平低于对照组,脑脊液葡萄糖、氯化物水平高于对照组(P < 0.05);治疗后1周、2周观察组CSS、NIHSS评分较对照组低(P < 0.05);观察组并发症发生率7.50%(3/40)低于对照组25.00%(10/40),P < 0.05;随访6个月观察组预后分级情况优于对照组(P < 0.05)。 结论 脑出血并发急性期脑积水患者中应用Ommaya囊治疗,可调控神经损伤因子水平,恢复血脑屏障,改善神经功能,还能降低并发症风险,提升临床疗效,促进预后恢复。 Abstract:Objective To investigate the application of Ommaya capsule in the treatment of cerebral hemorrhage complicated with acute hydrocephalus and its effect on blood-brain barrier function and prognosis. Methods A total of 80 patients with cerebral hemorrhage complicated with acute hydrocephalus from January 2021 to January 2023 were selected and divided into 40 cases each according to random number table method. The control group was given lumbocisterna interventional therapy, and the observation group was given Ommaya capsule interventional therapy. Compare the therapeutic effect of the two groups, as well as blood-brain barrier (BBB) index, serum S100β protein (S100β), cerebrospinal fluid cell count, glucose, myelin basic protein (MBP), National Institutes of Health Stroke Scale (NIHSS), specific enolase (NSE), chloride, Chinese Stroke Clinical Neurological Deficit Scale (CSS) score and occurrence of complications before and after treatment, were followed up for 6 months, and the prognosis of the two groups was statistically compared, after 6 months of follow-up, the prognosis of the two groups was statistically compared. Results The total effective rate of observation group was 90.00% (36/40), which is higher than that of control group (72.50% (29/40) (P < 0.05). The levels of serum S100β, MBP, BBB index, NSE and CSF cell number in observation group were lower than those in control group 1 week and 2 weeks after treatment, and the levels of CSF glucose and chloride were higher than those in control group (P < 0.05). The CSS and NIHSS scores of observation group were lower than those of control group 1 and 2 weeks after treatment (P < 0.05); The complication rate of the observation group was 7.50% (3/40) lower than that of the control group (25.00% (10/40) (P < 0.05). The prognosis of observation group was better than control group (P < 0.05) after 6 months of follow-up. Conclusion The application of Ommaya capsule therapy in patients with cerebral hemorrhage complicated with acute hydrocephalus can regulate the level of nerve injury factors, restore the blood-brain barrier, improve nerve function, and reduce the risk of complications, so as to improve the treatment effect and promote the prognosis. -
表 1 一般资料[($ \bar x \pm s $)/n(%)]
Table 1. General information [($ \bar x \pm s $)/n (%)]
资料 对照组(n = 40) 观察组(n = 40) t/χ2/u P 性别 0.503 0.478 男 28(70.00) 25(62.50) 女 12(30.00) 15(37.50) 年龄(岁) 50.34±6.18 50.76±6.39 0.299 0.766 出血量(mL) 40.15±2.68 39.72±2.71 0.714 0.478 发病至就诊时间(h) 6.15±2.28 6.09±2.49 0.112 0.911 术中颅内压 36.17±3.45 35.88±3.19 0.390 0.697 脑出血病位 1.200 0.753 基底节区 10(25.00) 8(20.00) 丘脑 11(27.50) 9(22.50) 脑室 17(42.50) 19(47.50) 脑叶 2(5.00) 4(10.00) 术前GCS评分(分) 0.629 0.529 9~12 15(37.50) 12(30.00) 6~8 20(50.00) 22(55.00) 3~5 5(12.50) 6(15.00) 表 2 治疗效果[n(%)]
Table 2. Treatment effect [ n(%)]
组别 n 显效 有效 无效 总有效率 观察组 40 22(55.00) 14(35.00) 4(10.00) 36(90.00) 对照组 40 14(35.00) 15(37.50) 11(27.50) 29(72.50) χ2 4.021 P 0.045* *P < 0.05。 表 3 血脑屏障功能指标比较($ \bar x \pm s $)(1)
Table 3. Comparison of blood-brain barrier function indicators ($ \bar x \pm s $)(1)
组别 n BBB指数 脑脊液细胞数(×106/L) 治疗前 治疗后1周 治疗后2周 治疗前 治疗后1周 治疗后2周 观察组 40 0.87±0.14 0.50±0.10a 0.22±0.05a 269.14±38.95 156.27±26.68a 85.29±8.23a 对照组 40 0.85±0.18 0.62±0.13a 0.31±0.08a 265.82±41.17 181.34±31.02a 92.57±11.74a t 0.555 4.627 6.034 0.371 3.875 3.211 P 0.581 <0.001* <0.001* 0.712 <0.001* 0.002* 表 3 血脑屏障功能指标比较($ \bar x \pm s $)(2)
Table 3. Comparison of blood-brain barrier function indicators ($ \bar x \pm s $)(2)
组别 n 脑脊液葡萄糖(mmol/L) 脑脊液(mmol/L) 治疗前 治疗后1周 治疗后2周 治疗前 治疗后1周 治疗后2周 观察组 40 0.95±0.20 2.18±0.11a 2.32±0.10a 110.26±6.28 120.25±5.71a 122.34±6.13a 对照组 40 0.97±0.16 2.06±0.13a 2.21±0.12a 109.58±5.43 115.79±6.04a 118.05±6.22a t 0.494 4.457 4.454 0.518 3.394 3.107 P 0.623 <0.001* <0.001* 0.606 0.001* 0.003* *P < 0.05;与同组治疗前比较,aP < 0.05。 表 4 神经损伤因子($ \bar x \pm s $)
Table 4. Neurological injury factors ($ \bar x \pm s $)
组别 n S100β(μg/L) MBP(μg/L) NSE(μg/L) 治疗前 治疗后1周 治疗后2周 治疗前 治疗后1周 治疗后2周 治疗前 治疗后1周 治疗后2周 观察组 40 1.42±0.27 0.93±0.16# 0.66±0.14# 30.25±4.20 16.39±3.12# 8.21±2.05# 32.76±5.83 20.16±4.29# 12.58±4.08# 对照组 40 1.39±0.31 1.08±0.20# 0.84±0.17# 29.51±3.77 20.47±4.09# 12.35±3.28# 32.03±6.14 25.32±5.12# 17.44±5.53# t 0.462 3.704 5.169 0.829 5.016 6.769 0.545 4.886 4.473 P 0.646 <0.001* <0.001* 0.410 <0.001* <0.001* 0.587 <0.001* <0.001* *P < 0.05;与同组治疗前比较,#P < 0.05。 表 5 神经功能($ \bar x \pm s $)
Table 5. Neurological function ($ \bar x \pm s $)
组别 n NIHSS评分(分) CSS评分(分) 治疗前 治疗后1周 治疗后2周 治疗前 治疗后1周 治疗后2周 观察组 40 21.15±2.08 13.69±1.64△ 8.72±1.33△ 17.78±2.25 9.98±1.43△ 6.29±1.19△ 对照组 40 20.68±2.13 15.74±1.80△ 10.02±1.57△ 18.03±2.31 11.25±1.62△ 8.05±1.36△ t 0.999 5.324 3.996 0.490 3.717 6.160 P 0.321 <0.001* <0.001* 0.625 <0.001* <0.001* *P < 0.05;与同组治疗前比较,△P < 0.05。 表 6 并发症[n(%)]
Table 6. Complications [n(%)]
组别 n 脑疝 感染 下肢麻木 低颅压
综合征总发生率 观察组 40 0(0.00) 1(2.50) 1(2.50) 1(2.50) 3(7.50) 对照组 40 1(2.50) 2(5.00) 6(15.00) 1(2.50) 10(25.00) χ2 4.501 P 0.034* *P < 0.05。 表 7 预后情况[n(%)]
Table 7. Prognosis [n(%)]
组别 n 1级 2级 3级 4级 5级 观察组 39 0(0.00) 1(2.56) 1(2.56) 17(43.59) 20(51.28) 对照组 39 0(0.00) 3(7.69) 7(17.95) 16(41.03) 13(33.33) u 2.047 P 0.041* *P < 0.05。 -
[1] Hostettler I C,Seiffge D J,Werring D J. Intracerebral hemorrhage: An update on diagnosis and treatment[J]. Expert Rev Neurother,2019,19(7):679-694. doi: 10.1080/14737175.2019.1623671 [2] Holste K G,Xia F,Ye F,et al. Mechanisms of neuroinflammation in hydrocephalus after intraventricular hemorrhage: A review[J]. Fluids Barriers CNS,2022,19(1):28. doi: 10.1186/s12987-022-00324-0 [3] Rostgaard N,Olsen M H,Ottenheijm M,et al. Differential proteomic profile of lumbar and ventricular cerebrospinal fluid[J]. Fluids Barriers CNS,2023,20(1):6. doi: 10.1186/s12987-022-00405-0 [4] Yuan Z B,Cao Z J,Li Z,et al. Transfrontal external ventricular drainage combined with OMMAYA Sac implantation under laser navigation were performed: A technical note[J]. J Craniofac Surg,2023,34(7):2157-2160. doi: 10.1097/SCS.0000000000009346 [5] 常国楫,黄瑛,张燕玲,等. Ommaya囊与腰大池介入对结核性脑膜脑炎并脑积水的疗效对比[J]. 昆明医科大学学报,2021,42(4):122-127. doi: 10.12259/j.issn.2095-610X.S20210423 [6] 张齐龙,叶琳,肖绍武,等. Ommaya囊植入治疗结核性脑膜炎合并脑积水的临床转归观察[J]. 中国全科医学,2011,14(36):4210-4212. [7] 刘如欲. Ommaya囊在颅脑术后颅内感染合并积水治疗中的临床应用[D]. 延安:延安大学,2023. [8] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国脑出血诊治指南(2019)[J]. 中华神经科杂志,2019,52(12):994-1005. doi: 10.3760/cma.j.issn.1006-7876.2019.12.003 [9] 中华医学会神经外科学分会脑血管病学组,中国医师协会神经外科医师分会脑血管病专委会. 脑血管病相关性正常颅压脑积水中国专家共识[J]. 中华医学杂志,2020,100(39):3049-3057. doi: 10.3760/cma.j.cn112137-20200623-01926 [10] Bodien Y G,Barra A,Temkin N R,et al. Diagnosing level of consciousness: The limits of the glasgow coma scale total score[J]. J Neurotrauma,2021,38(23):3295-3305. doi: 10.1089/neu.2021.0199 [11] Li JJ,Quan K,Wang Y,et al. Effect of stress hyperglycemia on neurological deficit and mortality in the acute ischemic stroke people with and without diabetes[J]. Front Neurol,2020,24(11):576895. [12] Mistry E A,Yeatts S D,Khatri P,et al. National institutes of health stroke scale as an outcome in stroke research: Value of ANCOVA over analyzing change from baseline[J]. Stroke,2022,53(4):e150-e155. [13] Wilson L,Boase K,Nelson L D,et al. A manual for the glasgow outcome scale-extended interview[J]. J Neurotrauma,2021,38(17):2435-2446. doi: 10.1089/neu.2020.7527 [14] Yang W S,Shen Y Q,Zhang X D,et al. Hydrocephalus growth: Definition,prevalence,association with poor outcome in acute intracerebral hemorrhage[J]. Neurocrit Care,2021,35(1):62-71. doi: 10.1007/s12028-020-01140-w [15] Huo J,Qi Z,Chen S,et al. Neuroimage-based consciousness evaluation of patients with secondary doubtful hydrocephalus before and after lumbar drainage[J]. Neurosci Bull,2020,36(9):985-996. doi: 10.1007/s12264-020-00542-2 [16] 符俊骐,王加充,曹作为,等. 颅内压监测指导下穿刺引流+Ommaya囊置入术治疗基底节区出血破入脑室[J]. 中国临床神经外科杂志,2022,27(6):484-485. [17] Woo B,Gwak H S,Kwon J W,et al. Lumboperitoneal shunt combined with ommaya reservoir enables continued intraventricular chemotherapy for leptomeningeal metastasis with increased intracranial pressure[J]. Brain Tumor Res Treat,2022,10(4):237-243. doi: 10.14791/btrt.2022.0022 [18] Singh R,Prasad R S,Singh R C,et al. Evaluation of pediatric hydrocephalus: Clinical,surgical,and outcome perspective in a tertiary center[J]. Asian J Neurosurg,2021,16(4):706-713. doi: 10.4103/ajns.AJNS_132_21 [19] Dominguez J F,Shah S,Li B,et al. Porencephalic cyst after endoscopic third ventriculostomy and Ommaya reservoir placement: Case report and review of the literature[J]. Childs Nerv Syst,2021,37(9):2917-2921. doi: 10.1007/s00381-021-05042-w [20] illmer L,Erhardt E B,Caprihan A,et al. Blood-brain barrier disruption measured by albumin index correlates with inflammatory fluid biomarkers[J]. J Cereb Blood Flow Metab,2023,43(5):712-721. doi: 10.1177/0271678X221146127 [21] 曹洪涛,邹伟,于学平. 脑出血后继发性神经损伤发生过程中microRNAs调控作用机制的研究进展[J]. 山东医药,2021,61(27):94-98. doi: 10.3969/j.issn.1002-266X.2021.27.025 [22] Zhai T,Fu Z L,Qiu Y B,et al. Application of combined cerebrospinal fluid physicochemical parameters to detect intracranial infection in neurosurgery patients[J]. BMC Neurol,2020,20(1):213. doi: 10.1186/s12883-020-01781-6 [23] Lu W X,Jiang C,Wang Z,et al. Lactic acid,neuron-specific enolase,and blood-brain barrier index after a severe traumatic brain injury: A prospective study[J]. Br J Neurosurg,2020,12(5):1-5. [24] Schmidt A P,Carmona M J C. Serum biomarkers of brain injury: S100B protein,cognitive dysfunction,and major non-cardiac surgery[J]. Braz J Anesthesiol,2020,70(6):570-572. doi: 10.1016/j.bjan.2020.10.003 [25] 汪潇,孟令文. 颅脑外伤术后血清S100 β及脑脊液P38蛋白与认知功能的关系[J]. 中国医药导报,2023,20(7):97-100,109. [26] 叶艳艳,吴若雅,夏雯丽,等. 血清S100B和髓鞘碱性蛋白对早产儿脑损伤的早期诊断价值[J]. 中国妇幼保健,2021,36(3):575-578. [27] Yan Z,Chu L,Jia X Q,et al. Myelin basic protein enhances axonal regeneration from neural progenitor cells[J]. Cell Biosci,2021,11(1):80. doi: 10.1186/s13578-021-00584-7 [28] Echeverría-Palacio C M,Agut T,Arnaez J,et al. Neuron-specific enolase in cerebrospinal fluid predicts brain injury after sudden unexpected postnatal collapse[J]. Pediatr Neurol,2019,10(1):71-77. [29] 王莉,张国军. 血清神经元特异性烯醇化酶与外伤性脑损伤患者及临床特征的关系[J]. 首都医科大学学报,2021,42(5):715-720. doi: 10.3969/j.issn.1006-7795.2021.05.004 [30] Golubovsky J L,Liao J,Hogue O,et al. Complications associated with ventriculoperitoneal shunt surgery for normal pressure hydrocephalus using stereotactic navigation and abdominal laparoscopy: A single-institution case series[J]. Oper Neurosurg(Hagerstown),2022,23(3):188-193. doi: 10.1227/ons.0000000000000290